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MR1-restricted mucosal-associated
invariant T cells and their
activation during infectious diseases
Lauren J. Howson, Mariolina Salio and Vincenzo Cerundolo*
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
MR1-restricted mucosal-associated invariant T (MAIT) cells recognize vitamin B metabo-
lites, which are generated by a broad range of bacteria, from Escherichia coli to
Mycobacterium tuberculosis and BCG. MAIT cells have been described as innate sensors
of infection as they accumulate early in infected tissues. MAIT cells maintain an activated
phenotype throughout the course of infections, secrete inflammatory cytokines, and have
the potential to directly kill infected cells, playing an important role in shaping the host
response. In this review, we will discuss the current knowledge regarding the molecular
mechanisms that underline MAIT cells activation in sterile and non-sterile inflammatory
conditions.
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Introduction
Innate-like lymphocytes, such as invariant natural killer T (iNKT) cells, have gained great interest
since their discovery, as these cells lie at the interface between innate and adaptive immune
responses. iNKT cells are memory cells bearing a semi-invariant T cell receptor (TCR) through
which they recognize self- and bacterial-derived lipid antigens presented by CD1d molecules.
During pathogen infection, iNKT cells facilitate adaptive immune responses by inducing dendritic
cellmaturation (1). Over the last few years, in addition to iNKT cells, another innate-like lymphocyte
cell subset has been the focus of much research: mucosal-associated invariant T (MAIT) cells, recog-
nizing a unique family of bacterial-derivedmetabolites in the context of themajor histocompatibility
complex (MHC) class I-like molecule MR1.
MR1 Structure and Function
The MR1 gene was first described in 1995 in a genome screen aimed at identifying novel MHC-
related genes (2). The human MR1 gene is located on chromosome 1, like CD1 genes, and despite a
similar intron/exon organization to classical MHCmolecules, it is non-polymorphic. MR1 is highly
conserved among mammalian species, with 90% sequence homology between human and mouse
MR1-ligand binding domains and a high level of functional cross-reactivity, a feature reminiscent of
CD1molecules (3, 4). Similar toMHC class I molecules, MR1 associates with β2-microglobulin and
interacts with the peptide-loading complex during biosynthesis in the endoplasmic reticulum (5,
6). In 2003, the connection between MR1 and MAIT cells was made by demonstrating the central
role of MR1, along with commensal flora and B cells, for MAIT cell development (7). Although
MR1 is ubiquitously transcribed, its physiological expression at the cell surface has been difficult to
demonstrate, with the exception of B cell subsets in the intestinal mucosa (8). A study ofmouseMR1
reported that only the folded form of MR1 was able to activate MAIT cells and certain mutations in
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the putative binding groove disrupted MAIT cell activation,
through presentation of yet unknown antigens (9). These results
led to great interest in determining the identity of the antigens
presented.
The observation that MAIT cells have anti-microbial activity
provided important insights into the identification of the MAIT
agonists presented by MR1. Kjer-Nielsen et al. (10) showed that,
similar to otherMHCclass I andMHCclass I-likemolecules,MR1
was unable to fold correctly in refolding buffer alone. This sug-
gested that it required the presence of its ligand in order to stabilize
its structure. Refolding was attempted in a number of conditions
using RPMI-1640 as a control. Surprisingly, it was found that
MR1 molecules were able to fold in this cell culture media,
which was known to contain a number of vitamins produced by
microbes, but not present in mammals. This observation-based
approach led Kjer-Nielsen and colleagues to test the ability of
vitamins to bind and stabilize MR1, and ultimately led to the
discovery of a new class of antigens: vitamin B metabolites (10).
The first crystal structure of the MR1-ligand complex was with
the folic acid (vitamin B9) metabolite 6-formylpterin (6-FP),
which was shown to be unable to activate MAIT cells (10).
To determine the identity of MAIT stimulatory ligands, MR1
molecules were refolded in the presence of the supernatant from
Salmonella typhimurium bacterial cultures, as it was known that
Salmonella-infected cells strongly activate MAIT cells (11, 12).
By high-resolution mass spectrometry (MS) [ESI–TOF-MS],
MR1 was shown to associate with a compound at m/z 329.1100,
with an atomic composition matching that of several riboflavin
(vitamin B2) derivatives: 6,7-dimethyl-8--ribityllumazine
(RL-6,7-diMe), 7-hydroxy-6-methyl-8--ribityllumazine (RL-6-
Me-7-OH), and reduced 6-hydroxymethyl-8--ribityllumazine
(rRL-6-CH2OH). In functional assays, these compounds were
stimulatory and induced CD69 expression as well as interferon-
gamma (IFNγ) and tissue necrosis factor-alpha (TNFα)
production by MAIT cells (10).
In order to understand the origin of the above MAIT cell
ligands, Lactocossus lactis mutants of the four-gene operon,
which controls riboflavin biosynthesis, were studied (13). These
results confirmed that riboflavin is necessary and sufficient to
generate natural MAIT cell ligands. Furthermore, these results
pointed to the compound 5-amino-6--ribitylaminouracil (5-
A-RU) as an intermediate necessary for MAIT cell activation.
This intermediate does not bind to MR1, but forms MAIT-
stimulating ligands through a non-enzymatic condensation with
glyoxal or methylglyoxal species, which can be of bacterial or
host cell origin (such as byproducts of glycolysis). The yields of
these condensation reactions are the unstable, yet potent inter-
mediates 5-(2-oxoethylideneamino)-6--ribitylaminouracil (5-
OE-RU) and 5-(2-oxopropylideneamino)-6--ribitylaminouracil
(5-OP-RU). These molecules can be captured and stabilized
through Schiff bases with Lys43 in the MR1 groove. Furthermore,
these compounds are the substrates for conversion to RL-6,7-
diMe.Mass spectrometry analysis ofMR1 refolded in the presence
of culture supernatants from S. typhimurium, E. coli (DH5α), or
rRL-6-CH2OH also revealed species with matching properties to
the synthetic 5-OP-RU, raising the possibility that the compound
initially identified as MR1 ligand was indeed 5-OP-RU (10, 13).
These results provide evidence that MAIT cells are able to sense a
wide range of bacteria through detection of vitamin metabolites,
including transitory intermediates, presented by MR1 molecules.
MAIT Cell Phenotype
Mucosal-associated invariant T cells were identified based on
their surface phenotype and mucosal tissue localization. The
MAIT cell invariant TCR Vα7.2–Jα33/12/20 in humans was first
described in 1993 as one of the few preferentially used TCRs in
the double-negative T cell compartment (14). This finding was
the first evidence of a new subset of T cells possibly recognizing
a limited set of antigens in the context of non-polymorphic
antigen presenting molecules. It was not until 1999 that the
MAIT cell subset was defined as a conserved subpopulation
distinct from MHC class I- and CD1-restricted cells with an
activated/memory phenotype (15). They also reported that the
human MAIT cell TCR β chain usage was primarily TRBV6 or
TRBV20. Initial research into MAIT cells has been hampered
by the lack of specific reagents; however, the generation of a
monoclonal antibody specific for the Vα7.2 TCR chain (16)
and MR1 tetramers (17) have recently enabled the functional
and phenotypic analysis of MAIT cells and brought them to the
forefront of innate-like lymphocyte research. MAIT cells are
defined as CD3+ Vα7.2+ CD161++ and either CD8+ or double-
negative T cells (12, 16). MR1-loaded tetramer experiments have
also identified a small subset of MAIT cells that are CD4+ (17).
All human MAIT cell subsets express the transcription factor
PLZF, known to direct the effector program of the iNKT cell
lineage (18). However, murine MAIT cells do not express PLZF
(16), thus the functional relevance of this observation is currently
unclear. MAIT cells can also be defined based on co-expression
of interleukin (IL)-18R (12) and CD26 (19). Furthermore, in
adults, peripheral blood MAIT cells have an effector memory
phenotype defined as CD45RO+, CD62Llo, CD95hi CD122int,
CD127int, and they express tissue-homing chemokine receptors:
CCR5, CCR6, CXCR6, and CCR9 (20). By contrast, MAIT cells
do not express CCR7 that is a marker for homing to lymph nodes.
The distinct memory phenotype and peripheral location of these
cells are linked to their unique developmental pathway.
MAIT Cell Development
Mucosal-associated invariant T cells develop and undergo selec-
tion in the thymus. Like iNKT cells, MAIT cells are selected by
CD4/CD8double-positive (DP) thymocytes (21).MR1 expression
on DP thymocytes is essential, as MR1-deficient mice do not
develop T cells expressing the MAIT cell TCR at detectable levels
(7). Although thymic selection occurs independently of B cell
and commensal flora (16), B cells are essential for MAIT cell
peripheral expansion and memory phenotype acquisition. How-
ever, the endogenous antigen(s) capable of selecting MAIT cells
in the thymus to date remain unclear. Furthermore, unlike iNKT
cells, human MAIT cells egress the thymus as naïve cells, that in
the periphery acquire a memory phenotype prior to birth (22).
Inmice, the interaction ofMAIT cells with B cells in the periph-
ery drives the acquisition of the MAIT cell memory phenotype
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(16). In humans, a recent study analyzed MAIT cell development
in second trimester fetal tissues, and reported acquisition of
innate-like anti-microbial activity already in utero (22). This study
suggested that MAIT cell maturation begins in the secondary
lymphoid organs, where they reported Vα7.2+ CD161+ cells
acquire expression of the transcription factor PLZF, CD62L, and
CD45RO. In fetal liver andmucosal tissues, Vα7.2+ CD161+ cells
expressed high levels of PLZF, IL-18Rα, CD62L, and CD45RO
and were capable of responding to bacterial antigen stimulation
both through proliferation and production of IFNγ and IL-22.
While murine studies have revealed the importance of the micro-
biota in shaping MAIT cell differentiation, as they are absent
in germ-free mice (7), this study suggests that human MAIT
cells develop prenatally, before establishment of the commensal
microflora, although the factors driving this maturation remain to
be identified (22). However, it remains unclear whether Vα7.2+
CD161+ T cells described by Leeansyah and colleagues are MR1-
restrictedMAIT cells, asMR1-tetramer staining orMR1-blocking
antibody experiments were not performed (22).
The interaction of MR1 expressing B cells and MAIT cells in
the periphery is necessary for MAIT cell expansion in mice (16).
Likewise in humans, individuals with mutated Bruton’s tyrosine
kinase, and thus with disrupted B cell development, have reduced
MAIT cell TCR transcripts in the blood compared to healthy
controls (7). These results are consistent with the observation that
both primary B cells and B cell lines can efficiently present bacte-
rial antigens to MAIT cells in an MR1-dependent manner (23).
Together, the results from these studies suggest that MAIT cells
are selected and undergo maturation prior to exposure to com-
mensal bacteria. It can be speculated that peripheral expansion of
MAIT cells may occur via presentation of an endogenous antigen
present atmucosal sites or throughmaternally derived commensal
flora antigen, possibly carried in the amniotic fluid.
MAIT Tissue Distribution
Mucosal-associated invariant T cells are primarily located in the
mucosal compartments and blood. The expression of chemokine
receptorsCXCR6 andCCR9 at the surface ofMAIT cells suggested
that they traffic to the tissues, particularly the intestine, lung, and
liver (20). Indeed, these tissues have a higher proportion of MAIT
cells, composing 20–40% of liver T cells and 4–10% intestinal
T cells (20, 24). MAIT cells compose 1–8% of T cells in the
blood. Analysis of the Vα7.2–J33 and Vα7.2–Jα12 transcripts in
different tissues revealed that MAIT cells are also present in the
kidney and at a lower frequency in the tonsils and lymph nodes
(25). They also reported variable expression of these transcripts
in the prostate and ovary (25). Analysis of the α chains revealed
a predominance of Vα7.2–Jα33 in the blood and Vα7.2–Jα12
in tissues indicating that these two MAIT subsets might differ
in their tissue-homing properties (25). Further investigation is
needed to determine whether these two subtypes are function-
ally distinct in terms of their antigen/pathogen specificity or are
related to the infection history of the individual.
In humans, circulating MAIT cells are more abundant than
iNKT cells, while in mice they are far fewer (15, 16, 20). Studies
assessing the influence of age and gender ofMAIT cells found that
MAIT cells decrease with age, but are not significantly different
between males and females (26–28). The MAIT cell phenotype
also changes according to the tissue compartment. For example,
liver MAIT cells have a more activated phenotype compared to
blood MAIT cells and express higher levels of CD69, CD38 and
HLA-DR, possibly reflecting continuous antigen exposure (24).
MR1-Dependent and -Independent MAIT
Cell Activation
In 2010, two publications described a wide range of phylogenet-
ically diverse bacteria and yeast that were able to activate MAIT
cells. These microbes included: E. coli, Pseudomonas aeruginosa,
Klebsiella pneumoniae, Lactobacillus acidophilus, Staphylococ-
cus aureus, Staphylococcus epidermidis, Saccharomyces cerevisiae,
Candida glabrata, and Candida albicans (11, 12). Conversely,
viruses and few bacterial species such as Enterococcus faecalis and
Streptococcus group A did not elicit MR1-dependent MAIT cell
activation. The later discovery of the MAIT cell ligand offered
the explanation for the lack of response as these bacteria lack the
vitamin B metabolites that bind MR1 molecules and stimulate
MAIT cells (10).
Cytokine Production
Mucosal-associated invariant T cells can produce pro-
inflammatory cytokines upon activation (Figure 1). Stimulation
with phorbol 12-myristate 13-acetate (PMA) and ionomycin, as
well as bacteria, showed that human MAIT cells are capable of
producing IFNγ, TNFα, IL-2, and IL-17 but not IL-10 (20, 24).
Ex vivomultiparametric mass cytometry in three donors recently
confirmed that there are distinct subsets of circulating MAIT
cells releasing different cytokine combinations, most frequently
MIP1β, IFNγ, TNFα, and IL-2, and to a lesser extent IL-4 and
IL-10 (25). Furthermore, MAIT cells from the small intestine are
capable of producing IL-22 in response to E. coli, but this was not
observed in MAIT cells from the liver or lung (22). Thus, MAIT
cells have a mixed Th1/Th17 cytokine profile with differences
according to their peripheral location, possibly reflecting local
environmental imprinting.
Cytotoxicity
An important property ofMAIT cells is their ability to kill infected
cells (Figure 1). Cytotoxicity occurs primarily via granule exo-
cytosis and relies on the effector cell containing components
that enable destruction of a target cell. These include perforin
and granzymes that, in humans, consist of five isoforms with
different substrate specificities: granzyme (Gr) A, GrB, GrH, GrK,
and GrM (29). GrB and perforin have been directly linked to
the cytotoxic activity of CD8+ T cells (30). It has been shown
that MAIT cells are able to lyse bacteria-infected epithelial cells
(31) and E. coli-infected THP1 cells (32) in an MR1-dependent
manner. Interestingly, human MAIT cells have a unique cyto-
toxic profile, characterized by low perforin expression, but high
GrA and GrK, contained in CD107+ lytic granules (32). Upon
antigen recognition, an MR1-dependent GrB upregulation and
an MR1-independent perforin upregulation was observed, sug-
gesting that antigen pre-exposure licenses MAIT to acquire a
stronger cytotoxic phenotype (32). The ability to kill infected
target cells suggests that MAIT cells could have an important role
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FIGURE 1 | Proposed mechanisms of MAIT cell activation in infection
and sterile disease. Bacteria or yeast (1) can stimulate MAIT cell activation
following infection or phagocytosis by antigen presenting cells. These cells can
then present microbial-derived vitamin B metabolites via MR1 (associated with
β2-microglobulin) to the Vα7.2-bearing MAIT TCR. Upon infection, antigen
presenting cells also produce IL-12 and IL-18 cytokines that can activate MAIT
cells in an antigen-independent mechanism. The production of IL-7 from
hepatocytes can act synergistically to enhance MAIT cell activation. Viruses (2)
can stimulate MAIT cells through detection of their molecular patterns by pattern
recognition receptors, such as ssRNA by TLR8 on antigen presenting cells,
resulting in the production of IL-12 and IL-18. In sterile disease (3), such as
autoimmunity, cells that pathologically express cytokines IL-12 and IL-18 can
activate MAIT cells. The activation of MAIT cells (4) results in the production of
Th1 cytokines IFNγ and TNFα, Th17 cytokines IL-17 and IL-22 (particularly by
small intestine-derived MAIT cells), and release of perforin and granzyme B to
directly kill infected cells.
in controlling infections by intracellular bacteria, such as Shigella
and Salmonella, although the latter may escape MAIT cell detec-
tion by preventing vacuole–lysosomal fusion (33). Indeed, it has
been shown that, while HeLa cells infected with Shigella flexneri
can be readily killed by MAIT cells, HeLa cells infected with S.
typhimurium failed to be detected or lysed by MAIT cells (31).
MR1-Independent Activation
Like other innate-like cells, MAIT cells can also respond to infec-
tion in an MR1-independent manner. For example, the in vitro
MAIT cell response to cells infected with Mycobacterium bovis
Bacillus Calmette–Guérin (BCG) is largely MR1-independent
(34). The high expression of IL-18R onMAIT cells suggested that
IL-18 could be one of the cytokines able to activateMAIT cells (20,
35). Therefore, cytokine-dependent activation of MAIT cells was
explored in more detail and it was reported that MAIT cells
could produce IFNγ when their TCR is blocked and they are
cultured with IL-18 and IL-12 (36). Furthermore, cytokines can
synergize with TCR stimulation to enhance MAIT cell activation.
For example, liver-resident MAIT cells express high levels of IL-
7R and IL-7 potentiates TCR-dependent secretion of Th1 cytokine
and of IL-17A (24). These results suggest that multiple factors
could shapeMAIT cells responsiveness during bacterial infection,
and their ability to respond to cytokine stimulation, independent
of TCR cross-linking, may account for their response to microbes
not containing MR1 ligands, such as viruses and some bacterial
species (Figure 1).
MAIT Cells in Bacterial Infections
Murine infection models and natural human infections have been
researched in order to further our understanding of MAIT cells
and their activation during pathological conditions.
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In amousemodel of lung infectionwith live Francisella tularen-
sis (LVS), it was demonstrated that MAIT cells colonize the lung
in both early and intermediate phases of the infection, reach their
peak expansion in the late clearance phase of infection, and persist
following clearance of the bacteria (37). From day 8 of infection
onward, MAIT cells in the lung produced anti-bacterial cytokines
(IFNγ, TNFα, and IL-17A). The evidence for the importance of
MAIT cells in controlling infection came from MR1 knockout
mice, which showed a delay in clearance of the bacteria in the
lungs (but not in the spleen or liver) and delayed appearance of
adaptive immune responses in the lung (37). A similar increase in
bacterial load in comparison with wild type mice was found when
mice lacking MAIT cells were infected with K. pneumonia or M.
bovis BCG (34, 38). Together, these studies indicate that the role of
MAIT cells in controlling infection is not redundant, and is vital
for timely mounting of effective adaptive immune responses.
Tuberculosis
In humans, the contribution of MAIT cells to anti-bacterial
immunity has been studied mostly during Mycobacterium tuber-
culosis infection. MAIT cells have been shown to be able to
respond in vitro to M. tuberculosis infected primary lung epithe-
lium and dendritic cells (11, 39). In individuals with active M.
tuberculosis infection, it was found that circulating MAIT cells
were in lower absolute numbers and proportions compared to
healthy individuals (11, 12). This suggested that MAIT cells may
migrate to inflamed tissues, where they can have a localized
response to infection. There is also evidence that MAIT cells
are enriched in the lung of healthy donors and therefore could
respond early during the course of infection (11).
To assess whether the reduced number of MAIT cells is accom-
panied by an altered functionality, a study analyzed the cytokine
production by MAIT cells from individuals with tuberculosis
(TB) in response to different stimuli. Despite lower frequencies,
a higher proportion of MAIT cells in individuals with active TB
secreted IFNγ and TNFα in response to BCG stimulation as
compared to healthy controls (although the overall response was
very low) (40). More convincingly, a lower proportion of MAIT
cells responded to E. coli in the same cohort of infected individuals
compared to healthy controls. These results suggest that there
may be an overall enrichment of MAIT cells specific for BCG
compared to E. coli upon in vivo antigenic exposure.
This concept of expansion of pathogen-specific MAIT T cell
clones is suggested by a recent paper reporting that heterogeneity
in the TCR β chain usage by MAIT cell clones was directly
related to their ligand specificity, and thus, to responses to dif-
ferent microbes (41). While this is a very attractive possibility,
this observation requires further confirmation as the MAIT cells
assessed in the above study were defined as Vα7.2+ CD8+ cells
that produced TNFα in response to bacterial stimulation.Without
using MAIT specific markers, such as CD161, IL-18R, or CD26,
this strategy could have included a proportion of conventional
Vα7.2+ T cells. Furthermore, noMR1 blocking experiments were
included to demonstrate differential microbe recognition. Nev-
ertheless, a contribution of the TCRβ chain sequence to antigen
binding has been also suggested by a second study (42), where
six MAIT TCRs with differing β chains were refolded and their
biophysical parameters were measured. This study showed that
the CDR3β loop usage directly impacts MAIT cell recognition of
ligands through altering the TCR flexibility and contact withMR1
and the ligand (42); thus, suggesting a role of theTCRCDR3β loop
in fine-tuning MAIT cells’ specificity.
These findings open up an exciting area of research, suggesting
that this innate-like lymphocyte subset may be capable of forming
memory-like responses upon selective expansion of MAIT cell
clones following lifetime microbe exposure. The ability to form
memory responses could have implications for the therapeutic use
of MAIT cells.
Other Bacterial Infections
Decreased numbers of circulating MAIT cells have also been
reported in individuals with cystic fibrosis during infection with
the opportunistic pathogen P. aeruginosa (43). In these individ-
uals, the lower MAIT cell numbers also correlated with lung
disease severity, systemic inflammation, and clinical status. How-
ever, whether the reduction in numbers was a consequence of
their localization to the airway mucosa, or by itself influenced
colonization and disease progression, was not addressed.
The relevance of MAIT cells in a model of invasive enteric
infection was addressed in a study investigating the efficacy of an
attenuated strain of Shigella dysenteriae (31). A specific reduction
in circulating MAIT cells was observed at day 11 in subjects
who received bacteria compared to controls. Individuals who
responded to the vaccine, producing a specific IgA response, also
had a trend toward a higher baseline proportion ofMAIT cells and
at day 11 had an increased proportion of activated MAIT cells as
determined by HLA-DR upregulation.
Mucosal-associated invariant T cells have also been investigated
in cases of severe infection with Vibrio cholerae. It was reported
that MAIT cells activation, as measured by CD38 expression,
peaks 7 days after the onset of infection (44). In adults, the pro-
portion of MAIT cells did not change upon infection, but inter-
estingly, in children a significant and persistent decrease in MAIT
cell proportion was observed. The reason for the adult/child dis-
crepancy is not clear and requires further investigation. Although
V. cholerae is known to have a riboflavin biosynthetic pathway,
in vitro experiments aimed at demonstrating the role of vitamin
B2 metabolites in this recognition were not performed.
A specific decrease in MAIT cell counts (but not iNKT or γδ T
cells) was also observed in severe infections. Critically ill patients
admitted to the intensive care unit (ICU) with sepsis had lower
circulating levels of MAIT cells compared to healthy controls
and non-septic critically ill individuals (45). Patients with lower
MAIT numbers were also more susceptible to hospital-acquired
infections.Of interest, it was reported that streptococcal infections
(which do not stimulate MAIT cells in vitro) induced a less pro-
nounced decrease in MAIT cell numbers than non-streptococcal
infections, although there was a large overlap between groups that
prevented statistical significance.
MAIT Cells in Viral Infection
Although it has been established that virally infected cells do
not directly activate MAIT cells (12), several publications have
investigated the numbers and activation of MAIT cells in human
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immunodeficiency virus (HIV) infection. The rationale behind
investigatingMAIT cells in the context of HIV is due to the effects
this virus has on increasing the permeability of intestinal epithelia.
This alteration causes translocation of microbial products from
the gastrointestinal tract, resulting in systemic immune activation
(46, 47).
Human Immunodeficiency Virus
Two groups reported that circulatingMAIT cells are reduced early
in HIV infection compared to healthy controls (48, 49). This
trend was also observed in individuals with chronic HIV, and
numbers could not be restored following anti-retroviral therapy
(49). Consistent with these findings, staining with MR1 tetramers
loaded with 5-OP-RU confirmed that the tetramer-positiveMAIT
population is reduced during HIV infection (50).
The activation and function of circulating MAIT cells in HIV
were also assessed, and it was found that they express lower
levels of CD69 and produce less IFNγ and TNFα in response to
ex vivo bacterial stimulation compared to healthy controls (49).
Interestingly, after anti-retroviral therapy, a partial restoration
of cytokine production was observed. However, this impaired
activation and function of MAIT cells were not confirmed in a
separate study (50).
The authors also investigatedMAIT cells in the rectal and colon
mucosa of HIV infected individuals, which were reduced, like cir-
culating MAIT cells. However, mucosal numbers were better pre-
served and could be restored after anti-retroviral therapy (49, 51).
The decline and possible impaired activation of MAIT cells in
patients infected with HIV are likely to affect the MAIT cells’
ability to control bacteria and yeast infections and, as a result,
leave the host extremely vulnerable and contributing to acquired
immune deficiency syndrome (AIDS) pathogenesis.
Hepatitis B and C
As previously discussed, a large proportion of liver-resident T
cells are MAIT cells. These liver-resident immune cells are of
great interest as viruses, such as hepatitis B virus (HBV) and
hepatitis C virus (HCV), can establish persistent infections in
the liver. To determine whether liver MAIT cells could respond
to innate signals upon viral infection, Toll-like receptor (TLR)
agonists were used to stimulate liver intra-sinusoidal cells. It
was found that TLR8 agonist ssRNA40 was able to activate
liver MAIT and NK cells to produce large amounts of IFNγ
(52). The response was MR1-independent and driven by IL-
12 and IL-18 released by TLR8-stimulated monocytes. A sim-
ilar activation of hepatic MAIT cells was observed in indi-
viduals infected with HBV and HCV. This preservation of
anti-viral activity of MAIT cells in diseased livers could pro-
vide a possible therapeutic target for the treatment of viral
infection.
MAIT Cells in Sterile Disease
The capacity of MAIT cells to respond to cytokine stimulation, as
described above, raises the possibility that these cellsmay also play
a role in sterile inflammation such as autoimmune disorders and
cancer.
Multiple Sclerosis (MS)
The role of MAIT cells in MS has been extensively researched.
MAIT cells’ TCR was identified in central nervous system MS
lesions using single-strand conformation polymorphism analysis
in autoptic specimens (53). Normal frequency of MAIT cells
was found in the blood of MS patients and MAIT cells were
also detected in the cerebrospinal fluid of relapsing patients.
This suggested a role for MAIT cells in the progression of this
disease, which was functionally explored by a study using a
mouse model for MS, experimental autoimmune encephalitis
(EAE). In transgenic mice overexpressing the MAIT cell TCR,
MAIT cells protected against EAE through suppression of Th1
cytokine production and increased production of IL-10 primarily
by B cells (54). It was also observed that, in MR1 knockout
mice, EAE was exacerbated, suggesting a new regulatory role for
MAIT cells.
Conflicting results have emerged from studies assessing the
distribution of circulating MAIT cells in MS patients. A study
of an Italian cohort assessing MAIT cells of monozygotic twins
with discordant disease states showed a greater number of circu-
lating CD8+ CD161++ cells in MS patients compared to their
healthy twin (55). By contrast, a study of a Japanese cohort showed
decreased circulating MAIT cells in MS patients compared to
healthy controls (56). This discrepancy between the two studies
findings underlines the difficulties of studies with human subjects
and suggests the variation in the commensal flora or lifetime
infection burden may have affected MAIT cell frequencies in the
two populations.
Psoriasis
It has previously been reported that IL-17A is a vital component
in the etiology of psoriasis (57). AsMAIT cells are able to produce
this cytokine, it was thought that they might be the CD8+ cells
previously observed in psoriatic lesions. It was found that MAIT
cells are indeed present in the psoriatic lesions along with Th17
cells (58). This provided evidence that MAIT cells may contribute
to psoriasis, however, their activation in this setting is yet to be
explored.
Rheumatic Diseases
Mucosal-associated invariant T cells have also been studied in the
context of rheumatic diseases. It was found that individuals with
systemic lupus erythromatosis (SLE) and rheumatoid arthritis
(RA) had lower circulating levels ofMAIT cells (59). Furthermore,
MAIT cells have been detected in the synovial fluid of RA patients
in higher proportions than in the blood. Individuals with SLE
had MAIT cells with impaired activation, as they had a lower
production of IFNγ when challenged with bacteria or stimulated
with PMA and ionomycin. This impaired function was more
prominent in individuals with lower MAIT cell numbers, sug-
gesting a correlation between MAIT cell numbers and function.
Conversely, in RA patients, the IFNγ secretion was preserved.
To assess whether the inhibitory molecule PD-1 correlated with
MAIT cell dysfunction, its expression onMAIT cells was assessed
and found to be higher on MAIT cells in individuals with SLE
compared to individuals with RA or healthy controls. However,
after PD-1 blockade, MAIT cell activation was only partially
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restored, indicating other negative regulationmechanismsmay be
contributing to MAIT cell dysfunction in SLE.
Inflammatory Bowel Disease and Celiac Disease
The location of MAIT cells in the small intestine mucosa makes
them of great relevance in the pathogenesis of intestinal inflam-
matory disorders, such as inflammatory bowel diseases (IBD):
Crohn’s disease and ulcerative colitis. A study reported that the
number of circulating MAIT cells was reduced in individuals
with Crohn’s disease and ulcerative colitis compared to healthy
controls (60). A similar observation was reported with circulating
MAIT cell numbers in individuals with celiac disease (61). It
was also reported that MAIT cells were higher in number in
inflamed compared to healthy tissues (60). Functional assessment
of MAIT cells from individuals with IBD showed increased IL-
17 production upon stimulation along with increased IL-22 in
ulcerative colitis but decreased IFNγ secretion in individuals with
Crohn’s disease. This first demonstration of activated MAIT cells
in inflamed gut tissues warrants further investigation as to their
potential pathogenic role.
Cancer
A less explored area is the potential role ofMAIT cells in cancer. A
publication has suggested MAIT cells may be present in renal and
brain cancers through detection of their TCR in these tissues (62).
This presence correlated with the presence of pro-inflammatory
cytokines in the tumor tissue, suggesting they could have anti-
neoplastic functions. However, this has not been explored any
further.
MAIT Cell as a Potential Therapeutic Target
With their ability to alter the cytokine microenvironment to pro-
inflammatory, direct killing of infected cells, potential to enhance
adaptive immune responses, and the recent discovery of their acti-
vating ligands,MAIT cellsmay be an ideal target tomanipulate for
enhancing immune responses. An understanding of the potential
of these cells could aid the designing ofmore targeted vaccines and
effective immunotherapies.
The use of bacteria as adjuvants to enhance immune responses
was first explored in 1891 when William Coley conducted intra-
tumoral injections of S. pyogenes and Serratia marcescens to cause
inflammation and subsequent destruction of the tumor cells (63).
This form of immunotherapy, in which bacteria are used to stimu-
late anti-tumor immune responses, has not been highly successful
with the notable exception of the intra-vesical instillation of BCG,
which is currently the gold standard treatment of non-invasive
bladder cancer. Although successful, it is still not well under-
stood what the immune principles are that underlie its success.
It has previously been discussed that MAIT cells are able to
respond to BCG-infected cells in vitro (34, 40). Understanding
whether MAIT cells are key players in mediating the success
of BCG immunotherapy may help in designing more targeted
therapies and also opens up the potential for MAIT cell-targeted
immunotherapies for other cancers.
Outstanding Questions
A number of questions still need to be addressed in the field of
MAIT cell research. First, the full spectrum of MAIT-activating
ligands remains to be explored. Whether other possible vitamin
metabolites or small organic compounds could bind MR1 and
stimulateMAIT cell responses is still an open question. Also, a pri-
ority will be identification of endogenous ligand(s) involved in
shapingMAIT cell selection andmaturation during development.
Second, although MAIT cells can respond to yeast species
in vitro, the role of MAIT cells during yeast infections in vivo
remains to be addressed.
Third, it is still not clearwhat factors determine the relative con-
tribution of antigen-dependent versus cytokine-dependentMAIT
cell response during an infection. Early findings suggest that the
presence of the ligand, mode of infection, and subcellular local-
ization of the bacteria may all impact the wayMAIT cells respond
during infection.
Finally, it is still not knownwhether theMAIT cell subset could
be an effective therapeutic target. The identification of potent
antigens for MAIT cells could provide a possible adjuvant in
vaccine and immunotherapies targeting both infections and also
non-sterile diseases.
Concluding Remarks
The role of MAIT cells during infection is only beginning to
be established, with their early infiltration into infected tissues,
production of pro-inflammatory cytokines, and role in assisting
an effective adaptive immune response. The effector functions of
MAIT cells in sterile disease conditions are also being explored.
Such an integral role in the progression of infection, and possibly
sterile diseases, makes these cells an ideal target for enhancing
immune responses.
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